Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now     
Bio B2BPhytohealth Corp. 〉PG2 Lyo.Injection 500mg

PG2 Lyo.Injection 500mg

PG2 Lyo.Injection 500mg

PG2® Lyophilized Injection is an injectable drug that is extracted,isolated and highly purified from the plant「huang qi」.This injection is intended for cancer patients unable to recover from moderate to severe fatigue, for which there are no drugs currently available. It has been approved by the Taiwan Food and Drug Administration (TFDA)

Request for Collaboration
Overview
  Since its introduction into the market in April 2012, PhytoHealth PG2® Lyo. Injection has been used to treat many cancer patients who suffered greatly during chemotherapy and radiation therapy. Clinicians have most often cited our treatment with great praise for patients who cannot endure and must discontinue chemotherapy. After using PhytoHealth PG2® Lyo. Injection, the physical conditions and hematopoiesis were restored, and the patients were able to complete the treatment course. Along with the increased number of clinical cases, an increasing number of oncologists have become more certain of the clinical contributions of PhytoHealth PG2® lyophilized injection. Over 20 seminars were conducted at regular medical conferences and near-month rotating seminars have been conducted at various hospitals at which physicians exchange their clinical experience. Theses related to PhytoHealth PG2® Lyo. Injection have been continuously presented to important international medical conferences. The PhytoHealth development and production group have made persistent efforts to develop an even more advanced lyophilized drug, and received approval from the Taiwan Food and Drug Administration (drug license no.: 058837), making it available for clinical use nationwide. The pharmacological mechanism of PhytoHealth PG2® Lyophilized Injection involves the enhancement of immune function and stimulation of bone marrow hematopoiesis. From this knowledge of basic pharmacology, scientific research has shown that through empirical clinical research, namely, rigorous clinical study design in accordance with Good Clinical Practice (GCP), our clinical results were published in the internationally renowned medical journals Clinical & Investigative Medicine (ref. 1) and Medical Oncology (ref. 2), confirming that PhytoHealth PG2® Lyo. Injection has excellent clinical efficacy. Follow-up researches on PhytoHealth PG2® Lyo. Injection have never stopped after IPO, and they continue to be focused primarily on the mechanisms of action of PG2, including:
  • research on immunoregulatory effects of PG2 
  • research on anti-inflammatory effects of PG2 
  • clinical research of PG2 efficacy in treating stroke 
  • research on the effect of PG2 on biomarkers of cancer-related fatigue
Features
  • An IV Infusion drug, originally extracted, isolated and purified from the Astragalus membranaceus (黃耆)
  • The first Taiwan Food and Drug Administration(TFDA) approved drug which used for Cancer-related Fatigue (CRF)
  • Bi-directional immune-modulator to reach  Th1/Th2 homostasis
  • Mobilize and activate of stem cell and modulate hematopoiesis of WBCs, RBCs and Platelets.
  • Anti-inflammation, antioxidant and enhancing immunity
  • Potential use for preventing chemotherapy-induced side effects, the orphan disease, Idiopathic Thrombocytopenic Purpura(ITP) and stroke
Specifications
500 mg/per bottle
Application
Indicated for alleviating moderate to severe cancer-related fatigue
Collaboration Options
Product licensing
 
More Information
People who like this also like
  • Atopic dermatitis genetic screeningAtopic dermatitis genetic screening
  • GB KIWI e2000GB KIWI e2000
  • Neuro-trition-Hericium erinaceusNeuro-trition-Hericium erinaceus
  • U2™ Knee SystemU2™ Knee System
  • Smart Care MattressSmart Care Mattress
  • Facial Dermal ImplantFacial Dermal Implant
  • BIOLOX®OptionBIOLOX®Option
  • U2™ Knee APTU2™ Knee APT
  • USTAR™ SystemUSTAR™ System
  • ServicesServices